Ferrous Sulfate 7.5 mg Iron/0.5 mL Oral Syringe
Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.
676 recalls · Class II, newest first
Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.
Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.
Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.
Defective Container: broken or leaking bottles.
Chemical Contamination
Chemical Contamination
Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
Lack of assurance of sterility and cGMP deviations observed at the manufacturing site.
Lack of Assurance of Sterility: There is a potential for leakage at the IV bottle port.
CGMP Deviations
CGMP Deviations
CGMP Deviations
Failed Dissolution Specifications
Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.
Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Lack of Assurance of Sterility
Failed Dissolution Specifications.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.